Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2004 Jul 9

PMID 15239392

Citations 2

Authors

Tetsuzo Tauchi

Kazuma Ohyashiki

Affiliations

Soon will be listed here.

Abstract

Imatinib therapy is an important contribution to the management of patients with chronic myelogenous leukemia (CML). Despite high rates of hematologic and cytogenetic responses to imatinib therapy, the emergence of resistance to imatinib has been recognized as a major problem in the treatment of CML. Experimental and clinical studies suggest that imatinib as a single drug may not be sufficient to eradicate BCR-ABL-positive stem cells. Therefore, whether combinations of imatinib with other agents can increase the length of molecular remission and whether such combinations can prolong survival should be determined by large-scale clinical studies. In this review, we discuss efficacious combinations for future clinical trials. These regimens combine imatinib with conventional chemotherapeutic agents or with inhibitors of other signal transduction molecules that may be preferentially activated in CML cells.

Citing Articles

Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Sheng Z, Wang S, Green M EMBO J. 2009; 28(7):866-76.

PMID: 19229297 PMC: 2670863. DOI: 10.1038/emboj.2009.35.

Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.

Roeder I, Glauche I J Mol Med (Berl). 2007; 86(1):17-27.

PMID: 17661001 DOI: 10.1007/s00109-007-0241-y.

References

Hamdane M, DHalluin J . Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene. 1997; 15(19):2267-75. DOI: 10.1038/sj.onc.1201411. View

Marcucci G, Byrd J, Dai G, Klisovic M, Kourlas P, Young D . Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2002; 101(2):425-32. DOI: 10.1182/blood-2002-06-1899. View

Roumiantsev S, Shah N, Gorre M, Nicoll J, Brasher B, Sawyers C . Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002; 99(16):10700-5. PMC: 125018. DOI: 10.1073/pnas.162140299. View

Perkins C, Kim C, Fang G, Bhalla K . Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000; 95(3):1014-22. View

Daley G, Van Etten R, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247(4944):824-30. DOI: 10.1126/science.2406902. View

Raynaud F, Orr R, Goddard P, Lacey H, Lancashire H, Judson I . Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997; 281(1):420-7. View

Brodsky A . Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood. 2003; 101(5):2070; author reply 2070-1. DOI: 10.1182/blood-2002-09-2980. View

Ashar H, James L, Gray K, Carr D, Black S, Armstrong L . Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000; 275(39):30451-7. DOI: 10.1074/jbc.M003469200. View

Lopes de Menezes D, Mayer L . Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol. 2002; 49(1):57-68. DOI: 10.1007/s00280-001-0385-3. View

10.

Heinrich M, Griffith D, Druker B, Wait C, Ott K, Zigler A . Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96(3):925-32. View

11.

Sebti S, Hamilton A . Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 2001; 19(56):6584-93. DOI: 10.1038/sj.onc.1204146. View

12.

Nimmanapalli R, OBryan E, Bhalla K . Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001; 61(5):1799-804. View

13.

Blagosklonny M . Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia. 2002; 16(4):455-62. DOI: 10.1038/sj.leu.2402415. View

14.

Nimmanapalli R, Bhalla K . Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene. 2002; 21(56):8584-90. DOI: 10.1038/sj.onc.1206086. View

15.

Mahon F, Deininger M, Schultheis B, Chabrol J, Reiffers J, Goldman J . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000; 96(3):1070-9. View

16.

Soignet S, Frankel S, Douer D, Tallman M, Kantarjian H, Calleja E . United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19(18):3852-60. DOI: 10.1200/JCO.2001.19.18.3852. View

17.

Hochhaus A, Kreil S, Corbin A, La Rosee P, Muller M, Lahaye T . Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16(11):2190-6. DOI: 10.1038/sj.leu.2402741. View

18.

Tauchi T, Broxmeyer H . BCR/ABL signal transduction. Int J Hematol. 1995; 61(3):105-12. DOI: 10.1016/0925-5710(95)00361-u. View

19.

Jansen B, Wacheck V, Heere-Ress E, Hoeller C, Lucas T, Hoermann M . Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 2000; 356(9243):1728-33. DOI: 10.1016/S0140-6736(00)03207-4. View

20.

Gambacorti-Passerini C, Rossi F, Verga M, Ruchatz H, Gunby R, Frapolli R . Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis. 2002; 28(3):361-72. DOI: 10.1006/bcmd.2002.0526. View